Point-of Care Ultrasound for Patients With HIV
Introducing Point-of-care Ultrasound at the Bedside for Diagnosing Opportunistic Diseases in Patients With HIV
Lead Sponsor: Erasmus Medical Center
|Source||Erasmus Medical Center|
Rationale: Point-of-care ultrasound (POCUS) is increasingly used by various specialists in the Netherlands, but its role in managing patients with HIV is unclear. In settings endemic for tuberculosis, Fast Assessment with Sonography for HIV/Tuberculosis (FASH) has proven its value to detect extrapulmonary tuberculosis in patients with HIV. However, there is no data to support POCUS for patients with HIV in resource affluent settings.
Objective: The investigators aim to determine the feasibility and diagnostic value of POCUS in detecting opportunistic disease in HIV patients with advanced disease stages in the Netherlands.
Study design: The investigators will perform a prospective observational pilot study.
Study population: The investigators will include new adult patients with HIV presenting with a cluster of differentiation 4 (CD4) T-cell count below 350 cells/mm3, and all adult HIV patients requiring admission to hospital. Intervention (if applicable): The investigators will perform a focused ultrasound examination including FASH, and ultrasound of the lung, liver and kidneys. In case of positive findings additional examinations will be undertaken to determine the underlying pathology and/or treatment started as indicated. In case of negative findings, patients will be followed for 12 months to observe for (possibly missed) opportunistic infections.
Main study parameters/endpoints: Our primary outcomes include acceptability of POCUS by patients, interobserver variation in interpretation of POCUS images, and number of diagnosed AIDS and non-AIDS related problems. Secondary outcomes include sensitivity and specificity, negative predictive value and positive predictive value of our POCUS protocol. In addition, incidence rates of opportunistic infections will be compared to a historical matched control group.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The ultrasound examination is painless and without risk to the participants. It will take approximately 30 minutes and will be combined with routine visits to the hospital. Benefits include potential earlier detection of opportunistic disease, while adverse effects may arise from false positive findings requiring further examinations which may cause stress or anxiety. The rate of false positive findings in POCUS has not been formally investigated, but appears low. The effect of POCUS in advanced HIV/AIDS can only be studied in HIV patients.
|Overall Status||Not yet recruiting|
|Start Date||June 1, 2020|
|Completion Date||September 1, 2022|
|Primary Completion Date||September 1, 2021|
Intervention Type: Diagnostic Test
Intervention Name: Opportunistic infection Ultrasound (OpUS) screening
Description: this point-of-care ultrasound protocol will include lung ultrasound, assessment of pericardial and pleural effusions, ascites, abdominal lymphadenopathy and splenic micro abscesses, as well as a focused ultrasound of liver and kidneys.
Arm Group Label: Patients with HIV undergoing point of care ultrasound
Inclusion Criteria: - new patients with HIV presenting with a CD4 T-cell count below 350 cells/mm3 - patients with HIV who are admitted to hospital Exclusion Criteria: - absence of informed consent
- new patients with HIV presenting with a CD4 T-cell count below 350 cells/mm3
- patients with HIV who are admitted to hospital
- absence of informed consent
Minimum Age: 18 Years
Maximum Age: N/A
Healthy Volunteers: No
Last Name: Mischa Huson, MD, PhD
Email: [email protected]
Type: Principal Investigator
Investigator Affiliation: Erasmus Medical Center
Investigator Full Name: Mischa Huson
Investigator Title: Principal Investigator
|Has Expanded Access||No|
|Number Of Arms||1|
Label: Patients with HIV undergoing point of care ultrasound
|Study Design Info||
Intervention Model: Single Group Assignment
Primary Purpose: Diagnostic
Masking: None (Open Label)